In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method

6/15/2008 From Cancer Gene Therapy

Summary:
In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method
Cancer Gene Therapy advance online publication, May 9, 2008. doi:10.1038/cgt.2008....

Original link:http://dx.doi.org/10.1038/cgt.2008.21

Bookmark | Comment | Forward | Twitter |

More articles from Cancer Gene Therapy

Hapten-derivatized nanoparticle targeting and imaging of gene expression by multimodality imaging systems 2008-11-16 21:29
Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation 2008-11-16 21:29
Downregulation of Wnt2 and β-catenin by siRNA suppresses malignant glioma cell growth 2008-11-13 11:38
Translational strategies exploiting TNF-α that sensitize tumors to radiation therapy 2008-11-13 11:38
Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV 2008-11-13 11:38
Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent 2008-11-13 11:38
Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation 2008-11-13 11:38
Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma 2008-11-13 11:38

Comments:

- Comments

Username: Login Sign Up

What's fun in inezha?

Track your favorite blogs
Just-in-time notification
Web-based RSS reader
Share your subscriptions